Trial 'No Longer Warranted' After Judge's Stelara Reversal
The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia...To view the full article, register now.
Already a subscriber? Click here to view full article